EIAS can cause hyperglycemia, hypoglycemia, and ketoacidosis in people with diabetes. This case in an older adult with type 1 diabetes shows how EIAS can be managed in an outpatient setting.
Once-weekly insulins offer a way to simplify therapy and reduce the treatment burden for people with type 2 diabetes, and also have potential for individuals with type 1 diabetes.
SGLT2 inhibitors reduce the risk of incident gout and gout flares in patients with type 2 diabetes and offer cardiovascular benefits, compared with sulfonylureas.
Our tailored content service will keep you up to date…
Receive newsletters curated for the busy specialist by our expert editorial team
EIAS can cause hyperglycemia, hypoglycemia, and ketoacidosis in people with diabetes. This case in an older adult with type 1 diabetes shows how EIAS can be managed in an outpatient setting.
HC-HB is a rare movement disorder that can occur in patients with poorly controlled diabetes and hyperglycemia without ketoacidosis. The mainstay of treatment is prompt correction of hyperglycemia.
Diabetic radiculoplexus neuropathy, or Bruns–Garland syndrome, is a rare form of microvascular complication that more commonly affects the lumbosacral plexus and, very rarely, the cervical plexus.
With the growing importance of primary care in diabetes, this podcast discusses the evidence on continuous glucose monitoring (CGM) use, the role of primary healthcare, and practical tips for interpreting the ambulatory glucose profile (AGP) report.
It is well known that vitamin D has a profound effect on calcium and bone metabolism, but its influence on other organs (extraskeletal effect) has been proposed. Consistently, vitamin D deficiency is associated with an increased incidence of …
Type 2 DiabetesDiabetes and Cardiovascular Disease (D Bruemmer, Section Editor)
Type 2 diabetes (T2D) is a major health care problem in the US, affecting approximately 37 million Americans or ~ 10% of the adult population, and for every person with T2D, there ~ 2 individuals with prediabetes [ 1 ]. Cardiovascular disease (CVD) …
Type 2 diabetes mellitus (T2DM) is a global health concern, and its prevalence has been steadily increasing over the years [ 1 ]. The International Diabetes Federation (IDF) estimated that approximately 537 million adults (ages 20–79) were living …
The rising prevalence of type 2 diabetes (T2D) is posing major challenges for the healthcare systems of many countries, particularly in the Asia–Pacific Region, in which T2D can present at younger ages and lower body mass index when compared with …
An expert-led symposium exploring the prevention and management of type 2 diabetes through dietary interventions. Highlights include discussion of the recent EASD guidelines, therapeutic diets, food types and processing, plus psychological factors that influence patient success, and the drivers of healthy eating and diabetes control.
Stay up to date with the rapidly changing CGM landscape. Learn how to implement and integrate CGM into diabetes management to improve patient care and outcomes.
Expert guidance on the multidisciplinary approach to identifying and managing chronic kidney disease in patients with type 2 diabetes, plus patient scenarios to assist your decision-making and put the latest clinical guidelines into context.
This program is not available to users in the UK and US.
An independent educational program featuring simulated patient consultations. Make knowledge-based decisions on diagnosis and management of CKD with and without co-morbidities, and learn from experts Kevin Fernando and David Wheeler.
In Colombia, approximately 3.5 million people live with diabetes, with the majority having Type 2 diabetes (T2D) [ 1 ]. Diabetes complications, specifically cardiovascular and renal disease, impose a significant burden on Colombia's healthcare …
Glucagon-like peptide-1 receptor agonists (GLP1-RAs) are an effective class of drugs for the treatment of type 2 diabetes mellitus (T2D), with well-defined safety and tolerability profiles. Their use is associated with better glycemic control and …
Globally, 537 million adults were living with diabetes in 2021, and this figure is expected to increase to 783 million by 2045 [ 1 ]. An estimated 90% of people with diabetes have type 2 diabetes (T2D) [ 2 ].
Diabetes is a complex metabolic disorder with a higher risk of microvascular or macrovascular complications compared to the general population, which is associated with increased mortality [ 1 , 2 ]. In high-income countries, diabetes is one of the …
